Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

Company Overview - Fate Therapeutics (FATE) is expected to report a quarterly loss of $0.44 per share, reflecting a year-over-year change of +2.2$1.27 million, down 24.4% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised 0.22% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4] - The Most Accurate Estimate for Fate Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +3.82% [10][11] Historical Performance - In the last reported quarter, Fate Therapeutics was expected to post a loss of $0.42 per share but actually reported a loss of$0.40, achieving a surprise of +4.76% [12] - Over the last four quarters, the company has beaten consensus EPS estimates three times [13] Comparative Industry Analysis - In the Zacks Medical - Biomedical and Genetics industry, Guardant Health (GH) is expected to post a loss of $0.50 per share, with a year-over-year change of +68.4$199.86 million, up 28.9% from the previous year [17] - The consensus EPS estimate for Guardant Health has been revised 7.1% higher in the last 30 days, and it has an Earnings ESP of 1.75% combined with a Zacks Rank of 2 (Buy), indicating a likely earnings beat [18]